Happy (soon to be) July 4th Weekend
June 27th, 2011
No comments
Another birthday year about to be past … leaving early on Mondays … macro economic express! Read more…
Categories: Opinion
Archive
Archive for June, 2011
Embryonic Stem-Cell (hESC) Funding Challenge should be dismissed
June 26th, 2011
No comments
A challenge to funding of hESC studies should be dismissed after an appeals court found the government-backed research to be lawful, Read more…
Regenerative Medicine Weekly Trend Line
June 25th, 2011
No comments
Shares of regenerative medicine stem cell companies were UP from unheraled LOWS due to macro issues and negative market gyrations. Read more…
Categories: Regenerative Medicine Mid-Week Trend Line
The RegMed Daily Dialogue, 6/24/11, dancing the “limbo”
June 24th, 2011
No comments
The 6 W’s: Who, what, where, when, why and what of it… Read more…
Categories: Regenerative Medicine, Stem Cell Research, The RegMed Daily Dialogue
CIRM expands Funding Oppurtunities and Definitions
June 24th, 2011
No comments
The governing board of the California Institute for Regenerative Medicine (CIRM) approved a $30M initiative Read more…
The RegMed Daily Dialogue, 6/23/11, no luck, can’t hide from the sell-off
June 23rd, 2011
No comments
The 6 W’s: Who, what, where, when, why and what of it… Read more…
Categories: The RegMed Daily Dialogue
New Chairman of CIRM
June 23rd, 2011
No comments
Jonathan Thomas, PhD, JD, will be the new Chairman of the California Institute for Regenerative Medicine, Read more…
ImmunoCellular Therapeutics (IMUC.OB) to present at 2nd World Cancer Vaccines Summit
June 22nd, 2011
No comments
IMUC.OB’s President and CEO Manish Singh PhD will present at the 2nd World Cancer Vaccines Summit Read more…
Categories: ImmunoCellular Therapeutics, NASDAQ: IMUC.OB
The RegMed Daily Dialogue, 6/22/11, rough patches lower expectation
June 22nd, 2011
No comments
The 6 W’s: Who, what, where, when, why and what of it… Read more…
Categories: Regenerative Medicine, Stem Cell Research, The RegMed Daily Dialogue
Fibrocell Science (OTCBB: FCSC.OB), FDA approves BLA for laViv, personalized aesthetic cell therapy
June 22nd, 2011
No comments
laVív® (azficel-T) is the first and only personalized aesthetic cell therapy approved by the FDA Read more…
Categories: BLA Approval, Fibrocell Science, NASDAQ: FSC.OB
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.